YORK, Pa., March 29, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (Nasdaq: UNIS ; ASX: UNS) today announced it has commenced initial production of the Unifill® ready-to-fill (prefilled) syringe at its FDA-registered manufacturing facility in York, Pennsylvania.
The initial production of the Unifill syringe, the world's first prefilled syringe with safety features fully integrated within the glass barrel, will enable Unilife to further accelerate discussions with more than 20 pharmaceutical companies. These pharmaceutical companies are at various stages of review in the potential use of the Unifill syringe with a number of approved and pipeline injectable drugs and vaccines across more than a dozen therapeutic classes.
Once Unilife completes final product validation activities for the Unifill syringe during the second quarter of 2011, the Company can begin to fulfill initial sales orders to its existing pharmaceutical partner. The supply and sale of the Unifill syringe to other interested pharmaceutical companies is expected to commence shortly afterwards.
Initial production batches are expected to be utilized by pharmaceutical companies and contract manufacturing organizations (which fill prefilled syringes with injectable drugs on behalf of their pharmaceutical clients) for a number of activities. This will include the initiation of drug stability studies, market evaluations, and validating the integration of the product into fill-finish systems currently used to load a measured dose of an injectable drug or vaccine into equivalent standard prefilled syringes.
Mr. Alan Shortall, CEO of Unilife, said, "We look forward to being in a position to begin fulfilling initial sales orders for the Unifill syringe towards the end of June, and consolidating relationships with a number of interested pharmaceutical compani